NCT01141179View on ClinicalTrials.gov

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

PHASE1CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Renal Impairment

Interventions

DRUG

LEO 27847

2 mL (0.1 mg) dose of oral solution

Trial Locations (1)

M2P 1N6

Anapharm, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors

lead

LEO Pharma

INDUSTRY